Skip to content
OpenCapital
Get started

Danaher DHR Biotechnology — Intangible Amortization

Similar metrics at other companies

CPR
CPRXAmortization Expenses Of Intangible Asset
$9.7M+3.8%
PTC Therapeutics logo
PTCTLife Science — Intangible Amortization
$11.58M+205%
Ligand Pharmaceuticals logo
LGNDDevelopment and Licensing of Biopharmaceutical Assets — Amortization of intangibles
$8.1M-1.9%
Universal Display logo
OLEDAmortization Of Acquired Technology And Other Intangible Assets
$5.59M+22.9%
Methode Electronics logo
MEIMedical — Intangible Amortization
$0—
Opko Health logo
OPKPharmaceutical — Intangible Amortization
$16.44M+0.1%

Other financials

Income statement

See full
Revenue$6.3B+5.5%
Gross profit$3.6B+2.5%
Operating income$1.1B+48.3%
Net income$870.0M+56.8%
EPS (diluted)$1.23+59.7%

Balance sheet

See full
Cash & equivalents$4.3B+47.0%
Total debt$27.9B+50.1%
Total equity$52.6B+0.5%
Total assets$92.4B+13.2%

Cash flow

See full
Operating cash flow$1.5B+14.6%
CapEx$269.0M+8.5%
Free cash flow$1.3B+16.1%

Valuation

See full
Market cap$134.62B-7.4%
Enterprise value$158.13B-1.7%
P/E33.6×-9.0×
P/S5.4×-0.7×

Profitability

See full
Gross margin58.5%-1.1pp
Operating margin20.4%+2.0pp
Net margin15.9%+1.7pp
FCF margin21.8%+1.5pp

Returns & leverage

See full
Return on equity7.6%+1.0pp
Debt / equity0.5×+0.2×
Current ratio1.7×0.0×

Where this comes from

Reported directly by Danaher in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Danaher’s 10-Q, filed July 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about Danaher's biotechnology — intangible amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Danaher's biotechnology — intangible amortization?
Danaher (DHR) reported biotechnology — intangible amortization of $231M in Q2 2026.
How has Danaher's biotechnology — intangible amortization changed year-over-year?
Danaher's biotechnology — intangible amortization increased by 1.3% year-over-year, from $228M to $231M.
What is the long-term trend for Danaher's biotechnology — intangible amortization?
Over 3 years (2022 to 2025), Danaher's biotechnology — intangible amortization has grown at a 3.6% compound annual growth rate (CAGR), from $812M to $902M.
What does biotechnology — intangible amortization mean?
The periodic expense recognized for the consumption of intangible assets, such as patents, acquired technology, and customer relationships, within the biotechnology segment. This is heavily influenced by the company's history of acquisitions and the valuation of acquired intellectual property. It reflects the cost of maintaining a competitive technological edge.